TITLE

Stem cell revival

AUTHOR(S)
Coghlan, Andy
PUB. DATE
October 2012
SOURCE
New Scientist;10/27/2012, Vol. 216 Issue 2888, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on attempts to resume a human embryonic stem cells (hESCs) clinical trial program cancelled in 2011 by the biotechnology company Geron, noting that former Geron officials and the biotechnology firm BioTime have placed a bid for the stem cell assets of the original program.
ACCESSION #
82897058

 

Related Articles

  • BioTime acquires Geron's stem cell program. Brower, Vicki // Nature Biotechnology;Feb2013, Vol. 31 Issue 2, p94 

    The article focuses on the acquisition of stem cell program of the California-based Geron Corp. by California-based BioTime Inc. It mentions that both the companies made agreement on the proper working of human embryonic stem cell (hESC) program and also promised to contribute intellectual...

  • Geron ESC Assets Regenerate at Asterias Biotherapeutics. Powers, Marie // BioWorld Today;4/5/2013, Vol. 24 Issue 65, p1 

    The article reports that BioTime subsidiary Asterias Biotherapeutics acquired the human embryonic stem cell (ESC) assets left by Geron. The deal, which was cited in the S-1 filing sent to the U.S. Securities and Exchange Mission, covered purchase of various assets like the common stock, patents,...

  • Geron Shifts Focus to Cancer Treatments.  // Chain Drug Review;12/12/2011, Vol. 33 Issue 21, p81 

    The article reports that Geron Corp. will stop and leave its clinical trial of a therapy using human embryonic stem cells and will shift to focus on its experimental cancer therapies.

  • Asterias Already Re-assembling Geron ESC Team.  // BioWorld Today;4/5/2013, Vol. 24 Issue 65, p3 

    The article reports that Asterias reacquired its human embryonic stem (ESC) cell assets from BioTime, as the former was renamed from its past name as BioTime Acqusition. The deal could increase the asset value of Asterias to about 40 to 50 million dollars. The deal would oblige Asterias to start...

  • Embryonic stem cell pioneer Geron exits field, cuts losses. Frantz, Simon // Nature Biotechnology;Jan2012, Vol. 30 Issue 1, p12 

    The article reports that biotechnology company Geron has decided to drop its human embryonic stem cell (hESC) research program, citing financial reasons. The company announced that it will cease the phase 1 trial of its hESC-derived oligodendrocyte progenitor cell product, GRNOPC1, which targets...

  • ACT Carries Torch for hESC Therapies Post-Geron Exit. Moran, Nuala // BioWorld International;11/23/2011, Vol. 16 Issue 47, p1 

    The article presents a study by the Advanced Cell Technology Inc. (ACT) which explained the role of retinal pigmented epithelial (RPE) cells for human embryonic stem cell (hESC)-based therapies. The researchers found good results from their first two patients, one with Stargardt's disease and...

  • hESC Therapy Pioneer Geron Abandons Stem Cell R&D. Moran, Nuala // BioWorld International;11/16/2011, Vol. 16 Issue 46, p1 

    The article reports that Geron Inc. is abandoning the field of human embryonic stem cell (heSC) therapy and will stop recruiting to its Phase I acute spinal injury trial. It notes that Geron chief executive officer (CEO) John Scarlett reviewed the costs, value inflection points and clinical,...

  • Patentability of Inventions Related to Human Embryonic Stem Cells. Piirman, Margit // Juridica International;2011, Vol. 18, p94 

    The article analyzes the problems in the patentability of inventions related to human embryonic stem cell (hESC) therapy in Estonia. The clinical trial of hESC-derived oligodendrocyte progenitor cells from Geron Corp. is highlighted. Patentability issues in the European Court of Justice (ECJ)...

  • Funding windfall rescues abandoned stem-cell trial. Check Hayden, Erika // Nature;6/1/2014, Vol. 510 Issue 7503, p18 

    The article discusses trial on human embryonic stem cells started in California whether it can helpful in regrowing nerves in spinal-cord injury, and mentions challenges in this trial. It mentions Asterias Biotherapeutics Inc. located at Menlo Park, California started trial with 14.3 million...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics